Trade Mark Journal No.2025/052 26 December 2025

WO0000001891351 (42)

Office of origin: European Union Intellectual Property Office (EUIPO)

Date of International Registration:29 August 2025
Date of designation in the UK: 29 August 2025
Image for mark 1891351_TIF AttackPoint Discovery

International priority date claimed: 29 April 2025 (European Union Intellectual Property Office (EUIPO)) (019179588)
Class 42
Research and development services in the field of pharmaceuticals and drug discovery; development of processes and methods for medical and veterinary purposes; development of preparations for medical and veterinary purposes; scientific research for medical purposes, namely, screening for the identification of drug candidates; development of precision RNA therapeutics; development of tailored RNA-based corrective interventions to target the root causes of serious diseases; research and development of new medical products for others; development and identification of novel druggable sites for pharmacological intervention using a bioinformatic discovery platform in a wet lab; screening services, bioinformatics services and modelling services to harness natural processes and modulate gene expression through platforms to generate optimized small molecules, antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs).

Contera Pharma A/S

Representative: DE FRIES & TUFEKOVIC IP APS, Bredgade 30, DK-1260 Copenhagen K, DENMARK